104 related articles for article (PubMed ID: 38770705)
1. Fulminant hepatitis in a hepatitis B surface antigen-positive patient with adult T-cell leukemia-lymphoma after mogamulizumab monotherapy.
Nakashima T; Kusumoto S; Ishida T; Kato C; Hagiwara S; Narita T; Masaki A; Ito A; Ri M; Komatsu H; Inagaki H; Tanaka Y; Iida S
Hepatol Res; 2024 May; ():. PubMed ID: 38770705
[TBL] [Abstract][Full Text] [Related]
2. Fatal reactivation of hepatitis B virus infection in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.
Ifuku H; Kusumoto S; Tanaka Y; Totani H; Ishida T; Okada M; Murakami S; Mizokami M; Ueda R; Iida S
Hepatol Res; 2015 Dec; 45(13):1363-7. PubMed ID: 25753008
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of hepatitis B virus in a patient with adult T-cell leukemia-lymphoma receiving the anti-CC chemokine receptor 4 antibody mogamulizumab.
Nakano N; Kusumoto S; Tanaka Y; Ishida T; Takeuchi S; Takatsuka Y; Akinaga S; Mizokami M; Ueda R; Utsunomiya A
Hepatol Res; 2014 Mar; 44(3):354-7. PubMed ID: 23601025
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Post-CAR-T Infusion HBV Reactivation in Two Lymphoma Patients Despite Entecavir Preventive Therapy.
Ma Y; Yang L; Bao Y; Yang Y; Chen L; Zheng M
Front Immunol; 2021; 12():751754. PubMed ID: 34691067
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia-lymphoma patients with resolved HBV infection following systemic chemotherapy.
Totani H; Kusumoto S; Ishida T; Masuda A; Yoshida T; Ito A; Ri M; Komatsu H; Murakami S; Mizokami M; Ueda R; Niimi A; Inagaki H; Tanaka Y; Iida S
Int J Hematol; 2015 Apr; 101(4):398-404. PubMed ID: 25633779
[TBL] [Abstract][Full Text] [Related]
6. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study.
Tsai YF; Yang CI; Du JS; Lin MH; Tang SH; Wang HC; Cho SF; Liu YC; Su YC; Dai CY; Hsiao HH
PeerJ; 2019; 7():e7481. PubMed ID: 31565551
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Yamauchi N; Maruyama D; Choi I; Atsuta Y; Sakai R; Miyashita K; Moriuchi Y; Tsujimura H; Kubota N; Yamamoto G; Igarashi T; Izutsu K; Yoshida S; Kojima K; Uchida T; Inoue Y; Tsukamoto N; Ohtsuka E; Suzuki S; Inaguma Y; Ichikawa S; Gomyo H; Ushijima Y; Nosaka K; Kurata M; Tanaka Y; Ueda R; Mizokami M; Kusumoto S
Cancer Sci; 2021 May; 112(5):1943-1954. PubMed ID: 33576088
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
9. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era.
Mak JWY; Law AWH; Law KWT; Ho R; Cheung CKM; Law MF
World J Gastroenterol; 2023 Sep; 29(33):4942-4961. PubMed ID: 37731995
[TBL] [Abstract][Full Text] [Related]
10. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
[TBL] [Abstract][Full Text] [Related]
12. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
Huang H; Li X; Zhu J; Ye S; Zhang H; Wang W; Wu X; Peng J; Xu B; Lin Y; Cao Y; Li H; Lin S; Liu Q; Lin T
JAMA; 2014 Dec; 312(23):2521-30. PubMed ID: 25514302
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation-a position paper.
Sarmati L; Andreoni M; Antonelli G; Arcese W; Bruno R; Coppola N; Gaeta GB; Galli M; Girmenia C; Mikulska M; Pane F; Perno CF; Picardi M; Puoti M; Rambaldi A; Svicher V; Taliani G; Gentile G
Clin Microbiol Infect; 2017 Dec; 23(12):935-940. PubMed ID: 28668466
[TBL] [Abstract][Full Text] [Related]
15. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma.
Matsue K; Kimura S; Takanashi Y; Iwama K; Fujiwara H; Yamakura M; Takeuchi M
Cancer; 2010 Oct; 116(20):4769-76. PubMed ID: 20597091
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
17. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
18. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
19. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]